Carl Zeiss Meditec AG (XSWX:AFX) Cyclically Adjusted Revenue per Share: CHF0.00 (As of Dec. 2025)


XSWX:AFX Carl Zeiss Meditec AG XSWX:AFX
67 GF Score
Price CHF25.22
GF Value CHF65.97
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG Cyclically Adjusted Revenue per Share?

Carl Zeiss Meditec AG XSWX:AFX +0.48% 67 Cyclically Adjusted Revenue per Share is CHF0.00 as of Dec. 2025. GuruFocus rates XSWX:AFX with a GF Score™ of 67/100 and a GF Value™ of CHF65.97 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Carl Zeiss Meditec AG's adjusted revenue per share for the three months ended in Dec. 2025 was CHF5.336. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is CHF0.00 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Carl Zeiss Meditec AG's average Cyclically Adjusted Revenue Growth Rate was 6.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Carl Zeiss Meditec AG was 11.40% per year. The lowest was 5.30% per year. And the median was 8.65% per year.

As of today (2026-07-02), Carl Zeiss Meditec AG's current stock price is CHF25.22. Carl Zeiss Meditec AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was CHF0.00. Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Carl Zeiss Meditec AG was 13.68. The lowest was 1.10. And the median was 6.28.


Carl Zeiss Meditec AG  (XSWX:AFX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Carl Zeiss Meditec AG was 13.68. The lowest was 1.10. And the median was 6.28.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Carl Zeiss Meditec AG Cyclically Adjusted Revenue per Share Related Terms


Carl Zeiss Meditec AG Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Carl Zeiss Meditec AG's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG Cyclically Adjusted Revenue per Share Chart

Carl Zeiss Meditec AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.24 27.31 0.00 0.00 0.00

Carl Zeiss Meditec AG Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XSWX:AFX vs ISRG, BDX, MDLN: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carl Zeiss Meditec AG Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio falls into.


XSWX:AFX
67GF Score
Carl Zeiss Meditec AG XSWX:AFX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carl Zeiss Meditec AG Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Carl Zeiss Meditec AG's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=5.336/129.3606*129.3606
=5.336

Current CPI (Dec. 2025) = 129.3606.

Carl Zeiss Meditec AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 3.719 100.017 4.810
201606 3.407 100.717 4.376
201609 3.947 101.017 5.054
201612 3.703 101.217 4.733
201703 4.031 101.417 5.142
201706 3.394 102.117 4.299
201709 4.142 102.717 5.216
201712 3.865 102.617 4.872
201803 4.192 102.917 5.269
201806 4.054 104.017 5.042
201809 4.417 104.718 5.456
201812 4.071 104.217 5.053
201903 4.361 104.217 5.413
201906 4.517 105.718 5.527
201909 5.235 106.018 6.388
201912 4.473 105.818 5.468
202003 4.084 105.718 4.997
202006 3.025 106.618 3.670
202009 4.493 105.818 5.493
202012 4.478 105.518 5.490
202103 4.954 107.518 5.960
202106 5.338 108.486 6.365
202109 5.422 109.435 6.409
202112 4.731 110.384 5.544
202203 5.073 113.968 5.758
202206 5.482 115.760 6.126
202209 6.121 118.818 6.664
202212 5.187 119.345 5.622
202303 5.560 122.402 5.876
202306 5.841 123.140 6.136
202309 6.258 124.195 6.518
202312 5.031 123.773 5.258
202403 5.102 125.038 5.278
202406 5.783 125.882 5.943
202409 6.249 126.198 6.406
202412 5.250 127.041 5.346
202503 6.137 127.779 6.213
202506 5.820 128.412 5.863
202509 6.724 129.255 6.729
202512 5.336 129.361 5.336

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of CHF0.00 mean?
Carl Zeiss Meditec AG (XSWX:AFX) has a Cyclically Adjusted Revenue per Share of CHF0.00 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Carl Zeiss Meditec AG and its competitors.
Is Carl Zeiss Meditec AG's Cyclically Adjusted Revenue per Share too high?
Carl Zeiss Meditec AG's current Cyclically Adjusted Revenue per Share is CHF0.00. Overall, Carl Zeiss Meditec AG has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's Cyclically Adjusted Revenue per Share compare to ISRG and BDX?
Carl Zeiss Meditec AG's Cyclically Adjusted Revenue per Share of CHF0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Carl Zeiss Meditec AG and its competitors. Carl Zeiss Meditec AG's current Cyclically Adjusted Revenue per Share is CHF0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (XSWX:AFX) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF65.97, compared to a current price of CHF25.22 — trading 61.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is CHF0.00. Carl Zeiss Meditec AG's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current Cyclically Adjusted Revenue per Share is CHF0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of CHF25.22 is trading 61.8% below its estimated GF Value™ of CHF65.97. GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.

Key valuation signals for XSWX:AFX:

  • Cyclically Adjusted Revenue per Share: CHF0.00
  • GF Value™: CHF65.97 vs. price of CHF25.22 (61.8% below fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
67GF Score

Get the complete analysis for XSWX:AFX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF25.22
Price
CHF65.97
GF Value